AU754767B2 - Compositions and methods for treating elevated blood cholesterol - Google Patents
Compositions and methods for treating elevated blood cholesterol Download PDFInfo
- Publication number
- AU754767B2 AU754767B2 AU46989/99A AU4698999A AU754767B2 AU 754767 B2 AU754767 B2 AU 754767B2 AU 46989/99 A AU46989/99 A AU 46989/99A AU 4698999 A AU4698999 A AU 4698999A AU 754767 B2 AU754767 B2 AU 754767B2
- Authority
- AU
- Australia
- Prior art keywords
- geranylgeranyl
- geranylgeraniol
- hmg
- coa reductase
- reductase inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9052798P | 1998-06-24 | 1998-06-24 | |
US60/090527 | 1998-06-24 | ||
GBGB9817167.1A GB9817167D0 (en) | 1998-08-06 | 1998-08-06 | Compositions and methods for treating elevated blood cholesterol |
GB9817167 | 1998-08-06 | ||
PCT/US1999/013887 WO1999066929A1 (en) | 1998-06-24 | 1999-06-21 | Compositions and methods for treating elevated blood cholesterol |
Publications (2)
Publication Number | Publication Date |
---|---|
AU4698999A AU4698999A (en) | 2000-01-10 |
AU754767B2 true AU754767B2 (en) | 2002-11-21 |
Family
ID=26314174
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU46989/99A Ceased AU754767B2 (en) | 1998-06-24 | 1999-06-21 | Compositions and methods for treating elevated blood cholesterol |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1089731A4 (de) |
JP (1) | JP2002518448A (de) |
AU (1) | AU754767B2 (de) |
CA (1) | CA2335366A1 (de) |
WO (1) | WO1999066929A1 (de) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000071531A1 (en) | 1999-05-24 | 2000-11-30 | America River Nutrition, Inc. | Tocotrienols and geranylgeraniol from bixa orellana byproducts |
AR040588A1 (es) | 2002-07-26 | 2005-04-13 | Schering Corp | Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa |
CA2521149C (en) | 2003-04-08 | 2014-03-25 | Barrie Tan | Annatto extract compositions, including geranyl geraniols and methods of use |
WO2010098906A1 (en) * | 2009-02-24 | 2010-09-02 | Madeira Therapeutics | Liquid statin formulations |
US20120171286A1 (en) * | 2009-04-27 | 2012-07-05 | Beth Isreal Deaconess Medical Center | Methods and compositions for the treatment and diagnosis of statin-induced myopathy |
WO2013130654A1 (en) * | 2012-02-29 | 2013-09-06 | Coyote Pharmaceuticals, Inc. | Gga and gga derivatives, compositions thereof and methods for treating neurodegenerative diseases including paralysis including them |
TW201427938A (zh) * | 2012-10-01 | 2014-07-16 | Coyote Pharmaceuticals Inc | 香葉基香葉基丙酮(gga)和其衍生物之製備方法及彼等與脲或硫脲之共結晶作用 |
US9119808B1 (en) | 2012-10-08 | 2015-09-01 | Coyote Pharmaceuticals, Inc. | Treating neurodegenerative diseases with GGA or a derivative thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4933165A (en) * | 1989-01-18 | 1990-06-12 | Merck & Co., Inc. | Coenzyme Q10 with HMG-CoA reductase inhibitors |
US5316765A (en) * | 1989-09-07 | 1994-05-31 | Karl Folkers Foundation For Biomedical And Clinical Research | Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies |
US5447959A (en) * | 1989-10-13 | 1995-09-05 | Medafor | Method of using derivatives of long chain fatty alcohols to treat neuronal degradation |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES8105781A1 (es) * | 1979-07-27 | 1981-06-16 | Sankyo Co | Un procedimiento para la preparacion de sales y esteres, de monacolina k utiles como agentes antitlipercolesteremicos. |
US5622985A (en) * | 1990-06-11 | 1997-04-22 | Bristol-Myers Squibb Company | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor |
US5639653A (en) * | 1993-07-19 | 1997-06-17 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva Universtiy | Method for proliferating Vγ2Vδ2 T cells |
US6369103B1 (en) * | 1994-01-18 | 2002-04-09 | Bristol-Myers Squibb Company | Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor |
IL112639A0 (en) * | 1994-03-11 | 1995-05-26 | Bristol Myers Squibb Co | A pharmaceutical composition containing pravastin |
US5574025A (en) * | 1994-10-26 | 1996-11-12 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferases |
IT1276162B1 (it) * | 1995-11-23 | 1997-10-27 | Baldacci Lab Spa | Geranilgeranil-derivati,procedimento per la loro preparazione e relative composizioni farmaceutiche |
JPH1087480A (ja) * | 1996-09-13 | 1998-04-07 | Eisai Co Ltd | 抗動脈硬化治療剤 |
US5763646A (en) * | 1997-03-13 | 1998-06-09 | Ranbaxy Laboratories, Ltd. | Process for manufacturing simvastatin from lovastatin or mevinolinic acid |
-
1999
- 1999-06-21 EP EP99930451A patent/EP1089731A4/de not_active Withdrawn
- 1999-06-21 WO PCT/US1999/013887 patent/WO1999066929A1/en not_active Application Discontinuation
- 1999-06-21 AU AU46989/99A patent/AU754767B2/en not_active Ceased
- 1999-06-21 CA CA002335366A patent/CA2335366A1/en not_active Abandoned
- 1999-06-21 JP JP2000555615A patent/JP2002518448A/ja not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4933165A (en) * | 1989-01-18 | 1990-06-12 | Merck & Co., Inc. | Coenzyme Q10 with HMG-CoA reductase inhibitors |
US5316765A (en) * | 1989-09-07 | 1994-05-31 | Karl Folkers Foundation For Biomedical And Clinical Research | Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies |
US5447959A (en) * | 1989-10-13 | 1995-09-05 | Medafor | Method of using derivatives of long chain fatty alcohols to treat neuronal degradation |
Also Published As
Publication number | Publication date |
---|---|
EP1089731A4 (de) | 2003-06-18 |
CA2335366A1 (en) | 1999-12-29 |
AU4698999A (en) | 2000-01-10 |
EP1089731A1 (de) | 2001-04-11 |
JP2002518448A (ja) | 2002-06-25 |
WO1999066929A1 (en) | 1999-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8481570B2 (en) | 1-methylnicotinaide derivatives and formulations of treatment of lipoprotein abnormalities | |
CA2301732C (en) | Therapeutic combinations | |
EP1660066B1 (de) | Pharmazeutische zusammensetzung mit einer kombination aus metformin und einem statin | |
AP1207A (en) | Combination therapy. | |
US20070166321A1 (en) | Compositions and Methods for Reducing Cholesterol and Inflammation | |
AU754767B2 (en) | Compositions and methods for treating elevated blood cholesterol | |
US20150272944A1 (en) | Novel triglyceride reducing agent | |
EP0373507A1 (de) | Zusammensetzung eines HMG-CoA-Reductase-Inhibitors und anderen Serumcholesterol senkenden Mitteln und Verfahren zur Senkung von Serumcholesterol durch diese Zusammensetzung | |
US9642860B2 (en) | Combinations of corroles and statins | |
KR900006993B1 (ko) | 아테롬성 동맥경화증 치료제로서의 dl-5-[(2-벤질-3,4-디하이드로-2H-벤조피란-6-일)메틸]티아졸리딘-2,4-디온 | |
WO1992003130A1 (en) | Use of aryl hydroxyurea compounds for the treatment of atherosclerosis | |
US6998422B2 (en) | Lipid peroxide-lowering compositions | |
KR20070085508A (ko) | 지질 농후 플라크의 감소, 안정화 및 파열 방지 방법 | |
AU4699099A (en) | Compositions and methods for treating elevated blood cholesterol | |
US7037934B2 (en) | Blood lipid ameliorant composition | |
KR101086040B1 (ko) | 간섬유화 및 간경화 치료 효과를 갖는 아시아트산 유도체 | |
US5461072A (en) | Use of aryl hydroxyurea compounds for the treatment of atherosclerosis | |
WO2002098353A2 (en) | Compositions and methods for inhibiting bone resorption | |
CA2494801A1 (en) | Medicinal composition containing hmg-coa reductase inhibitor | |
MXPA00002087A (en) | Therapeutic combinations comprising amlodipin and atorvastatin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) |